Biohaven Pharmaceuticals is positioning itself for what could be a groundbreaking market entry, as the company prepares to launch Vyglxia, potentially the first approved treatment for spinocerebellar ataxia. The FDA is expected to issue its approval decision for the oral therapy sometime between October and the end of December, following some delays in the regulatory timeline.
Spinocerebellar ataxia represents a group of rare genetic disorders characterized by progressive nerve cell erosion that causes significant problems with movement, coordination, and brain function. Currently, no approved therapies exist for this debilitating condition, making Vyglxia's potential approval particularly significant for the estimated 15,000 patients in the United States.
Commercial Readiness and Market Strategy
CEO Vlad Coric emphasized the company's preparedness during a healthcare conference hosted by Cantor Fitzgerald, stating that Biohaven would be "ready to ship on Day 1" following FDA approval. The company has already established comprehensive launch infrastructure, including patient hubs, nurse managers, insurance coverage specialists, and the foundational elements of a specialized sales team.
"There's a number of patients who are waiting," Coric noted. "We're ready to go. We're just waiting on the FDA."
The commercial approach for Vyglxia will differ markedly from Biohaven's previous experience with the migraine drug Nurtec ODT. Coric envisions a "very different" launch strategy that will be smaller, more streamlined, and cost considerably less than their previous commercial efforts. The sales team for Vyglxia is expected to be less than 10% the size of what the company deployed for Nurtec.
Patient Population and Access Strategy
Biohaven estimates that approximately 6,000 to 7,000 patients will be reachable at Vyglxia's launch, representing about half of the total U.S. patient population. The company plans to focus its sales efforts on roughly two dozen "centers of excellence" for spinocerebellar ataxia, along with approximately 70 facilities specialized in movement disorders. According to Coric, the "vast majority" of patients are covered by these specialized sites.
Currently, around 400 people are already receiving Vyglxia through open-label and expanded access programs. The company plans to "immediately convert" these patients upon the drug's approval, providing an immediate patient base for commercial launch.
Recognizing that some individuals might suspect they have the disease but remain undiagnosed due to the lack of approved therapies, Biohaven intends to "pretty aggressively" sponsor genotype testing to identify additional potential patients.
Competitive Landscape and Market Advantages
Unlike the company's previous experience with Nurtec ODT, which faced competition from AbbVie's similar migraine treatment, Vyglxia will enter a market with no direct competitors. "Thankfully, we're not going to have the epic David versus Goliath, Biohaven versus AbbVie," Coric remarked, referencing the competitive dynamics the company previously navigated.
Despite the streamlined approach, Coric indicated that investors should expect a "modern day launch" incorporating some themes that defined Nurtec's successful market entry, which included innovative marketing strategies across various platforms.
Company Background and Transformation
The current Biohaven represents what some refer to as the "2.0" version of the original company. The predecessor organization achieved significant success with Nurtec ODT, recording more than $450 million in annual sales by the end of 2021. This success attracted Pfizer's attention, leading to a nearly $12 billion acquisition in spring 2022 focused on the migraine business. Following the deal's closure, the remaining assets were spun out into the current Biohaven entity.
European Regulatory Strategy
Beyond the U.S. market, Biohaven continues to pursue European approval for Vyglxia. The company withdrew its marketing application earlier this year after determining that a key regulatory committee would not grant Vyglxia a classification carrying substantial commercial benefits. This classification is reserved for chemicals not previously authorized in Europe, and Vyglxia works by breaking down into a drug already approved in both the U.S. and Europe for ALS treatment.
According to Coric, Biohaven has gathered additional data to strengthen its case and has notified European regulators of its intention to refile for approval, suggesting continued commitment to international market expansion.
